Novozymes Reports Q1 Earnings: Sales and Profit Surge

Novonesis A/S, a leading producer of enzymes and microorganisms, has reported a significant increase in Q1 net profit and sales. Net sales break down by market into cleaning and household maintenance products (28.5%), bioenergy (24.8%), food industry and human health (22.1%), technical and cereal industries (12.8%), and agriculture and animal feed industry (11.8%). Geographically, sales are distributed across Denmark, Europe/Middle East/Africa, North America, Asia/Pacific, and Latin America.

Copenhagen, Denmark – May 8, 2025. Novonesis A/S, a leading producer of enzymes and microorganisms, has reported a significant increase in Q1 net profit and sales. The company's strong financial performance is driven by robust organic sales growth and a resilient business model.

Financial Highlights

- Net Sales Growth: Novonesis reported an organic sales growth of 11% in the first quarter of 2025, with an adjusted EBITDA margin of 38.3% [1].
- Regional Performance: Sales growth was broad-based across regions, with emerging markets growing by 15% and developed markets increasing by 9%.
- Segment Performance: The company's sales areas, including Food & Health Biosolutions and Planetary Health Biosolutions, all showed double-digit growth. Specifically, Food & Health Biosolutions grew by 12%, and Planetary Health Biosolutions by 11% [1].

Geographic Breakdown

- Denmark: Sales in Denmark contributed significantly to the overall growth, with a strong performance in both Food & Health and Planetary Health segments.
- Europe, Middle East, and Africa: The region reported a 14% organic growth, driven by all sales areas.
- North America: Sales grew by 7%, with a focus on innovation and regional production capabilities.
- Asia-Pacific: The region saw a 9% growth, driven by double-digit growth in Energy and Tech sectors.
- Latin America: Sales in Latin America grew by 18%, with strong performance in emerging markets.

Outlook

Novonesis maintains its full-year outlook for 2025, expecting organic sales growth of 5-8% (6-9% excluding certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds [1].

Innovations and Strategic Initiatives

The company launched six innovations in the first quarter, including an advanced protease portfolio for swift and efficient stain removal, further enhancing its product offerings and market competitiveness.

Financial Calendar

Key financial dates for Novonesis in 2025 include:
- August 21, 2025: H1 2025 financial results
- November 6, 2025: Q3 2025 financial results
- February 25, 2026: Full-year financial statement 2025

Conclusion

Novonesis A/S's strong Q1 performance underscores the company's ability to meet increasing demand for biosolutions in a dynamic global market. The company's focus on innovation, regional production capabilities, and strategic initiatives positions it well for sustained growth in the coming years.

References

[1] https://www.marketscreener.com/quote/stock/NOVONESIS-A-S-1412985/news/Novonesis-delivered-a-strong-Q1-with-11-organic-growth-and-confirms-full-year-outlook-49869878/